Last reviewed · How we verify
NCT03779438
17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa
NA trial testing 17-OHPC in Placenta Previa in 300 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Aswan University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- 17-OHPC
- placebo to 17-OHPC — full drug profile →
Conditions studied
- Placenta Previa — all drugs for Placenta Previa →
Sponsor
Aswan University Hospital
Who can join
Adults 18 to 45, female only, with Placenta Previa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03779438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 17-OHPC
Trials testing the same drug.
- NCT03779451 — Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa · NA · unknown
Other recruiting trials for Placenta Previa
Currently open trials in the same condition.
- NCT07025954 — Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta · NA · recruiting
- NCT06849349 — EXAMINATION OF SOME MOLECULES IN PLACENTAS OF PATIENTS WITH PLACENTA PREVIA, PLACENTA PERCREATA · recruiting
- NCT06867874 — Syncytiotrophoblast-derived Extracellular Vesicles in Placenta Previa and Accreta Spectrum · NA · recruiting
Other Aswan University Hospital trials
Trials by the same sponsor.
- NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
- NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
- NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
- NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
- NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03779438 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
- Last refreshed: 15 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03779438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing